Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice
- 2 December 1993
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 55 (6) , 963-967
- https://doi.org/10.1002/ijc.2910550615
Abstract
Nude mice bearing xenografts of the androgen-independent human prostate-cancer cell line PC-3 were treated for 4 weeks with somatostatin analog RC-160, bombesin/gastrin-releasing peptide (GRP) antagonist (RC-3095), or the combination of both peptides. In the first experiment, treatment was started when the tumors measured approximately 10 mm3. Tumor volumes and weights were reduced by about 40% by RC-160 or RC-3095 administered by s.c. injections at doses of 100 μg/day/ animal and 20 μg/day/animal respectively. The combination of RC-3095 with RC-160 did not further potentiate suppression of tumor growth, but histologically the ratio of apoptotic and mitotic indices was significantly higher in the groups treated with the combination than in the other groups. Serum gastrin levels were significantly reduced in all treated groups. Therapy with RC-160 or the combination also significantly decreased serum growth-hormone levels. Specific high-affinity binding sites for bombesin, somatostatin and epidermal growth factor (EGF) were found on the tumor membranes. Receptors for EGF were significantly down-regulated by treatment with RC-3095, RC-160 and a combination of both analogs. Tumors from mice treated with RC-160 showed a significant increase in maximal binding capacity for somatostatin as compared with control tumors, demonstrating the absence of down-regulation. In the second experiment, treatment was started when the tumors were well developed and measured approximately 90 mm3. No significant reduction in volume, weight and growth rate of tumors was found in the groups treated with RC-160 or RC-3095. Our results suggest that somatostatin analog RC-160 and bombesin/GRP antagonist RC-3095 can inhibit the growth of androgen-independent prostate cancer when the therapy is started at an early stage of tumor development.Keywords
This publication has 16 references indexed in Scilit:
- Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160International Journal of Cancer, 1994
- Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancerBiomedicine & Pharmacotherapy, 1992
- Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160The Prostate, 1992
- Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N‐terminal d‐Trp or d‐TpiInternational Journal of Peptide and Protein Research, 1991
- IGF-I and IGF-Binding Proteins: Stimulatory and Inhibitory Factors Secreted by Human Prostatic Adenocarcinoma CellsGrowth Factors, 1991
- Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasiaThe Prostate, 1989
- Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostateThe Prostate, 1989
- Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell lineThe Prostate, 1989
- Growth factor involvement and oncogene expression in prostatic tumoursJournal of Steroid Biochemistry, 1988